Surgical volume threshold to improve 3-year survival in designated cancer care hospitals in 2004-2012 in Japan.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Mar 2022
Historique:
revised: 17 12 2021
received: 27 07 2021
accepted: 27 12 2021
pubmed: 6 1 2022
medline: 11 3 2022
entrez: 5 1 2022
Statut: ppublish

Résumé

In Japan, cancer care hospitals designated by the national government have a surgical volume requirement of 400 annually, which is not necessarily defined based on patient outcomes. This study aimed to estimate surgical volume thresholds that ensure optimal 3-year survival for three periods. In total, 186 965 patients who had undergone surgery for solid cancers in 66 designated cancer care hospitals in Osaka between 2004 and 2012 were examined using data from a population-based cancer registry. These hospitals were categorized by the annual surgical volume of each 50 surgeries (eg, 0-49, 50-99, and so on). Using multivariable Cox proportional hazard regression, we estimated the adjusted 3-year survival probability per surgical volume category for 2004-2006, 2007-2009, and 2010-2012. Using the joinpoint regression model that computes inflection points in a linear relationship, we estimated the points at which the trend of the association between surgical volume and survival probability changes, defining them as surgical volume thresholds. The adjusted 3-year survival ranges were 71.7%-90.0%, 68.2%-90.0%, and 79.2%-90.3% in 2004-2006, 2007-2009, and 2010-2012, respectively. The surgical volume thresholds were identified at 100-149 in 2004-2006 and 2007-2009 and 200-249 in 2010-2012. The extents of change in the adjusted 3-year survival probability per increase of 50 surgical volumes were +4.00%, +6.88%, and +1.79% points until the threshold and +0.41%, +0.30%, and +0.11% points after the threshold in 2004-2006, 2007-2009, and 2010-2012, respectively. The existing surgical volume requirements met our estimated thresholds. Surgical volume thresholds based on the association with patient survival may be used as a reference to validate the surgical volume requirement.

Identifiants

pubmed: 34985172
doi: 10.1111/cas.15264
pmc: PMC8898718
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1047-1056

Subventions

Organisme : The Japan Society for the Promotion of Science
ID : 19K19452
Organisme : The Ministry of Health, Labour and Welfare
ID : H30-Gantaisaku-Ippan-009

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Ann Surg. 2019 Nov;270(5):775-782
pubmed: 31498184
J Clin Oncol. 2000 Jun;18(11):2327-40
pubmed: 10829054
Ann Surg Oncol. 2014 Dec;21(13):4068-74
pubmed: 25005073
J Oncol Pract. 2017 Feb;13(2):95-102
pubmed: 28972834
Cancer Sci. 2021 Jun;112(6):2513-2521
pubmed: 33570834
Surgery. 2017 Feb;161(2):433-443
pubmed: 27590617
Int J Cancer. 2020 Dec 1;147(11):3102-3109
pubmed: 32506433
Int J Cancer. 2011 Apr 15;128(8):1918-28
pubmed: 20589676
Health Policy. 2018 Nov;122(11):1165-1176
pubmed: 30193981
Ann Surg. 2018 Nov;268(5):712-724
pubmed: 30169394
Jpn J Clin Oncol. 2015 Aug;45(8):719-26
pubmed: 25979245
Ann Surg. 2018 Feb;267(2):375-381
pubmed: 27893532
J Gastrointest Surg. 2009 Nov;13(11):1900-10; discussion 1910-2
pubmed: 19760305
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
N Engl J Med. 1979 Dec 20;301(25):1364-9
pubmed: 503167
Cancer Sci. 2021 Mar;112(3):1150-1160
pubmed: 33428808
JAMA Surg. 2017 Apr 1;152(4):336-342
pubmed: 28030713
Cancer Sci. 2022 Mar;113(3):1047-1056
pubmed: 34985172
World J Surg Oncol. 2017 Jul 17;15(1):134
pubmed: 28716145
J Clin Oncol. 2019 Dec 1;37(34):3234-3242
pubmed: 31251691
CA Cancer J Clin. 2009 May-Jun;59(3):192-211
pubmed: 19414631
Cancer Sci. 2020 Mar;111(3):985-993
pubmed: 31943492
N Engl J Med. 2002 Apr 11;346(15):1128-37
pubmed: 11948273

Auteurs

Sumiyo Okawa (S)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.

Takahiro Tabuchi (T)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Kayo Nakata (K)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Toshitaka Morishima (T)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Shihoko Koyama (S)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Satomi Odani (S)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Isao Miyashiro (I)

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH